Bluebird’s Zynteglo Launch Under Way, But First Revenue Will Take Months

First Sales Of Newly Approved Product Expected In Q1 2023

Bluebird bio will not see revenue for Zynteglo until it is infused into beta-thalassemia patients, which will take months due to the ex vivo gene therapy’s complex manufacturing and quality control process.

Genetic engineering concept. Medical science. Scientific Laboratory.
Manufacturing and quality control will take 70-90 days for each Zynteglo dose • Source: Shutterstock

The launch of bluebird bio’s newly approved gene therapy Zynteglo (betibeglogene autotemcel) in the US is under way, but the firm does not expect to recognize any revenue from its first commercial product until the first quarter of 2023. Bluebird will not record sales until the treatment is infused into beta-thalassemia patients, and because of the ex vivo gene therapy’s manufacturing process and quality control requirements, it will be next year by the time Zynteglo is administered commercially.

More from New Products

Unicycive Approaches Its First Approval, But In A Competitive Space

 

The company is planning to launch oxylanthanum carbonate for chronic kidney disease patients on dialysis with hyperphosphatemia.

Soleno’s Vykat Gains First Prader-Willi Syndrome Approval, Rivals To Follow

 

After a long wait for patients, Vykat has become the first drug approved for Prader-Willi syndrome symptoms, opening the market up for Soleno and future challengers.

GSK’s Blujepa Brings Innovation To The Antibiotic Space

 

The US FDA approved Blujepa for the treatment of uncomplicated urinary tract infections, marking the first new mechanism of action for the infection in more than 30 years.

With Fabhalta’s C3G Approval, Now Novartis Has To Find The Patients

 

Novartis US president Victor Bultó talked to Scrip about the company’s efforts to reach patients with rare kidney diseases who are candidates for Fabhalta.

More from Scrip

Quotables: Pharma Leaders On The Month’s Hot Topics

 

The highlights of recent comments and insights from industry executives on the key issues covered in Scrip.

RemeGen Fast-Tracks Potential World-First BLys/APRIL Agent For gMG In Global Phase III Trial

 

RemeGen is planning to complete enrolment in the global Phase III RemeMG study with telitacicept in generalized myasthenia gravis by the end of 2025 or early 2026. The Chinese firm has already sidelined two other global Phase III trials with the molecule to prioritize the indication.

Finance Watch: European And Japanese Biotechs See VC Investor Interest In March

 
• By 

Private Company Edition: The latest group of drug developers to announce venture capital financings is remarkable for its geographic diversity, from Character Biosciences’ $93m series B round in the US to Augustine’s $85m series B in Belgium to a $29.2m series C for Aculys in Japan.